Search Results - "Al Arashi, W"

Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling by Janssen, Alexander, Leebeek, Frank W. G., Cnossen, Marjon H., Mathôt, Ron A. A., Fijnvandraat, K., Coppens, M., Meijer, K., Schols, S. E. M., Eikenboom, H. C. J., Schutgens, R. E. G., Beckers, E. A. M., Ypma, P., Kruip, M. J. H. A., Polinder, S., Tamminga, R. Y. J., Brons, P., Fischer, K., Galen, K. P. M., Nieuwenhuizen, L., Driessens, M. H. E., Vliet, I., Lock, J., Hazendonk, H. C. A. M., Moort, I., Heijdra, J. M., Goedhart, M. H. J., Al Arashi, W., Preijers, T., Jager, N. C. B., Bukkems, L. H., Cloesmeijer, M. E., Collins, P. W., Liesner, R., Chowdary, P., Millar, C. M., Hart, D., Keeling, D.

“…Nonlinear mixed effect (NLME) models are the gold standard for the analysis of patient response following drug exposure. However, these types of models are…”
Get full text

Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling by Janssen, Alexander, Hoogendoorn, Mark, Cnossen, Marjon H., Mathôt, Ron A. A., Cnossen, M. H., Reitsma, S. H., Leebeek, F. W. G., Mathôt, R. A. A., Fijnvandraat, K., Coppens, M., Meijer, K., Schols, S. E. M., Eikenboom, H. C. J., Schutgens, R. E. G., Beckers, E. A. M., Ypma, P., Kruip, M. J. H. A., Polinder, S., Tamminga, R. Y. J., Brons, P., Fischer, K., Galen, K. P. M., Heubel‐Moenen, F. C. J. I., Nieuwenhuizen, L., Driessens, M. H. E., Vliet, I., Lock, J., Hazendonk, H. C. A. M., Moort, I., Heijdra, J. M., Goedhart, M. H. J., Al Arashi, W., Preijers, T., Jager, N. C. B., Bukkems, L. H., Cloesmeijer, M. E., Janssen, A., Collins, P. W., Liesner, R., Chowdary, P., Millar, C. M., Hart, D., Keeling, D.

“…In population pharmacokinetic (PK) models, interindividual variability is explained by implementation of covariates in the model. The widely used forward…”
Get full text

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study by Heijdra, Jessica M, Al Arashi, Wala, de Jager, Nico C B, Cloesmeijer, Michael E, Bukkems, Laura H, Zwaan, Christian M, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Cnossen, MH, Leebeek, FWG, Fijnvandraat, K, Mathôt, RAA, Meijer, K, Kruip, MJHA, Polinder, S, Coppens, M, Tamminga, RYJ, Laros-van Gorkom, BAP, Brons, P, Schols, SEM, van der Meer, FJM, Eikenboom, HCJ, Schutgens, REG, Fischer, K, Heubel-Moenen, F, Nieuwenhuizen, L, Ypma, P, Driessens, MHE, Zwaan, CM, van Vliet, I, Collins, PW, Liesner, R, Chowdary, P, Keeling, D, Lock, J, Hazendonk, HCAM, van Moort, I, Preijers, T, Heijdra, JM, de Jager, NCB, Goedhart, MCHJ, Bukkems, LH, Al Arashi, W, Cloesmeijer, ME, Janssen, A

“…IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures…”
Get full text

PB0832 Optimizing Treatment of Pregnant Women with von Willebrand Disease: A Retrospective Analysis of Factor Replacement Therapy during Delivery by Al Arashi, W., Cloesmejer, M., Leebeek, F., Kruip, M., Mathôt, R., Cnossen, M.

Get full text

A Generative and Causal Pharmacokinetic Model for Factor VIII in Hemophilia A: A Machine Learning Framework for Continuous Model Refinement by Janssen, Alexander, Smalbil, Louk, Bennis, Frank C., Cnossen, Marjon H., Mathôt, Ron A. A., Cnossen, M.H., Cnossen, M.H., Mathôt, R.A.A., Leebeek, F.W.G., Coppens, M., Fijnvandraat, K., Meijer, K., Schols, S.E.M., Eikenboom, H.C.J., Schutgens, R.E.G., Heubel‐Moenen, F., Nieuwenhuizen, L., Ypma, P., Driessens, M.H.E., Vliet, I., Kruip, M.J.H.A., Polinder, S., Brons, P., Meer, F.J.M., Fischer, K., Galen, K., Collins, P. W., Mathias, M., Chowdary, P., Keeling, D., Lock, J., Hazendonk, H.C.A.M., Preijers, T., Jager, N.C.B., Schutte, L., Bukkems, L.H., Goedhart, M.C.H.J., Heijdra, J.M., Romano, L., Al Arashi, W., Cloesmeijer, M.E., Janssen, A., Koopman, S.F., Mussert, C.

“…In rare diseases, such as hemophilia A, the development of accurate population pharmacokinetic (PK) models is often hindered by the limited availability of…”
Get full text

Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations by Janssen, Alexander, Bennis, Frank C, Cnossen, Marjon H, Mathôt, Ron A A

“…This work focusses on extending the deep compartment model (DCM) framework to the estimation of mixed-effects. By introducing random effects, model predictions…”
Get full text

Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease by Bukkems, Laura H., Heijdra, Jessica M., de Jager, Nico C.B., Hazendonk, Hendrika C.A.M., Fijnvandraat, Karin, Meijer, Karina, Eikenboom, Jeroen C.J., Laros-van Gorkom, Britta A.P., Leebeek, Frank W.G., Cnossen, Marjon H., Mathôt, Ron A.A.

“…Recent studies have reported that patients with von Willebrand disease treated perioperatively with a von Willebrand factor (VWF)/factor VIII (FVIII)…”
Get full text

A man who was unable to open his eyes by Al-Arashi, W, Geijteman, E C T, Schweitzer, D H

“…A 47-years-old man presented with the complaint that he could not open his eyes in the morning. Facial myxedema caused by hypothyroidism was evident. Pictures…”
Get more information